B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion |
| |
Authors: | Emilio Barbera-Guillem M Bud Nelson Barbara Barr Julie K Nyhus Kenneth F May Jr Lan Feng James W Sampsel |
| |
Institution: | (1) BioCrystal Ltd., 575 McCorkle Boulevard, Westerville, OH 43082-8888, USA, US |
| |
Abstract: | Accumulating data are showing that the humoral immune response against tumors could favor tumor progression. However, no
B lymphocyte pathology has been reported in cancer. Using anti-IgM Ab we nonspecifically depleted B cells in tumor-bearing
mice, a treatment that resulted in significant reduction of tumor burden. We analyzed the B lymphocyte phenotype of abdominal
lymph nodes and peripheral blood from advanced colon cancer patients by flow cytometry, and compared the B cell phenotype
with that found in samples from normal donors. In both lymph nodes and peripheral blood of cancer patients, abnormal populations
of B lymphocytes appeared that express an increased CD21 and/or sTn antigens on their cell surface. All patients showed a
reduction of CD19+ cells. In a limited clinical test, we analyzed the effects of a partial B cell depletion with Rituximab. The treated patients
did not develop any side-effects; the CD21-hyperpositive lymphocytes were reduced, but the proportion of sTn-positive lymphocytes
remained unaffected. Apparent reduction of the tumor burden was reported in 50% of the patients when the treatment was ended.
Received: 13 May 1999 / Accepted: 4 August 1999 |
| |
Keywords: | Cancer therapy B cell depletion CD21 hyperexpression |
本文献已被 PubMed SpringerLink 等数据库收录! |
|